These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19874164)

  • 1. Sleep impairment in ecstasy/polydrug and cannabis-only users.
    Fisk JE; Montgomery C
    Am J Addict; 2009; 18(5):430-7. PubMed ID: 19874164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiological evidence of atypical processing underlying mental set shifting in ecstasy polydrug and polydrug users.
    Roberts CA; Fairclough SH; McGlone FP; Fisk JE; Montgomery C
    Exp Clin Psychopharmacol; 2013 Dec; 21(6):507-15. PubMed ID: 24080019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
    J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cortical oxygenation suggests increased effort during cognitive inhibition in ecstasy polydrug users.
    Roberts CA; Montgomery C
    J Psychopharmacol; 2015 Nov; 29(11):1170-81. PubMed ID: 26333432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in prefrontal blood oxygenation during an acute multitasking stressor in ecstasy polydrug users.
    Roberts CA; Wetherell MA; Fisk JE; Montgomery C
    Psychol Med; 2015 Jan; 45(2):395-406. PubMed ID: 25066866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study.
    de Sola S; Tarancón T; Peña-Casanova J; Espadaler JM; Langohr K; Poudevida S; Farré M; Verdejo-García A; de la Torre R
    Psychopharmacology (Berl); 2008 Oct; 200(3):425-37. PubMed ID: 18581098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users.
    Schilt T; de Win MM; Jager G; Koeter MW; Ramsey NF; Schmand B; van den Brink W
    Psychol Med; 2008 Sep; 38(9):1309-17. PubMed ID: 17988417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self reported sleep quality and cognitive performance in ecstasy users.
    Montgomery C; Fisk JE; Wareing M; Murphy P
    Hum Psychopharmacol; 2007 Dec; 22(8):537-48. PubMed ID: 17960556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the functional significance of ecstasy-related memory deficits using a virtual paradigm.
    Montgomery C; Hatton NP; Fisk JE; Ogden RS; Jansari A
    Hum Psychopharmacol; 2010; 25(4):318-25. PubMed ID: 20521322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Male and female ecstasy users: differences in patterns of use, sleep quality and mental health outcomes.
    Ogeil RP; Rajaratnam SM; Broadbear JH
    Drug Alcohol Depend; 2013 Sep; 132(1-2):223-30. PubMed ID: 23453259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms.
    Milani RM; Parrott AC; Schifano F; Turner JJ
    Hum Psychopharmacol; 2005 Jun; 20(4):249-61. PubMed ID: 15816011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everyday memory deficits in ecstasy-polydrug users.
    Montgomery C; Fisk JE
    J Psychopharmacol; 2007 Sep; 21(7):709-17. PubMed ID: 17606476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ecstasy use and self-reported disturbances in sleep.
    Ogeil RP; Rajaratnam SM; Phillips JG; Redman JR; Broadbear JH
    Hum Psychopharmacol; 2011 Oct; 26(7):508-16. PubMed ID: 21953704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between the negative effects attributed to ecstasy use and measures of cognition and mood among users.
    Fisk JE; Montgomery C; Murphy PN
    Exp Clin Psychopharmacol; 2009 Oct; 17(5):326-36. PubMed ID: 19803632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?
    Morgan MJ; McFie L; Fleetwood H; Robinson JA
    Psychopharmacology (Berl); 2002 Jan; 159(3):294-303. PubMed ID: 11862362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases.
    Cole JC; Goudie AJ; Field M; Loverseed AC; Charlton S; Sumnall HR
    Drug Alcohol Depend; 2008 Apr; 94(1-3):183-90. PubMed ID: 18201842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. fNIRS suggests increased effort during executive access in ecstasy polydrug users.
    Roberts CA; Montgomery C
    Psychopharmacology (Berl); 2015 May; 232(9):1571-82. PubMed ID: 25391436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective memory deficits in illicit polydrug users are associated with the average long-term typical dose of ecstasy typically consumed in a single session.
    Gallagher DT; Hadjiefthyvoulou F; Fisk JE; Montgomery C; Robinson SJ; Judge J
    Neuropsychology; 2014 Jan; 28(1):43-54. PubMed ID: 24015828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everyday and prospective memory deficits in ecstasy/polydrug users.
    Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N
    J Psychopharmacol; 2011 Apr; 25(4):453-64. PubMed ID: 20123936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic?
    Fisk JE; Montgomery C; Wareing M; Murphy PN
    Hum Psychopharmacol; 2006 Aug; 21(6):355-66. PubMed ID: 16915582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.